Natsol Laboratories Profile
Key Indicators
- Authorised Capital ₹ 24.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 19.35 Cr
as on 13-12-2024
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 10.00 Cr
as on 13-12-2024
- Revenue -4.44%
(FY 2022)
- Profit 37.31%
(FY 2022)
- Ebitda 34.03%
(FY 2022)
- Net Worth -2.72%
(FY 2022)
- Total Assets -2.75%
(FY 2022)
About Natsol Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 24.00 Cr and a paid-up capital of Rs 19.35 Cr.
The company has closed loans amounting to ₹10.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jagarlamudi Babu, Venkata Gottumukkala, Siva Dandu, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100AP2009PTC111540
- Company No.
111540
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 2009
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Natsol Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagarlamudi Babu  | Additional Director | 08-Mar-2018 | Current |
| Venkata Gottumukkala | Whole-Time Director | 09-Oct-2009 | Current |
| Siva Dandu | Whole-Time Director | 24-Nov-2018 | Current |
| Venkatasita Kanumuri | Whole-Time Director | 24-Nov-2018 | Current |
Financial Performance and Corporate Structure Insights of Natsol Laboratories.
Natsol Laboratories Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 4.44% decrease. The company also saw a substantial improvement in profitability, with a 37.31% increase in profit. The company's net worth dipped by a decrease of 2.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Natsol Laboratories?
In 2022, Natsol Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cornileus Pharmaceuticals Private LimitedActive 22 years 11 monthsJagarlamudi Babu is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The South Indian Bank Limited Creation Date: 28 Dec 2018 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Natsol Laboratories?
Natsol Laboratories has a workforce of 23 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Natsol Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Natsol Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
